Financial_NNP Statements_NNP 129_CD PRINCIPAL_JJ SUBSIDIARIES_NNS Percentage_NN of_IN voting_VBG At_IN 31_CD December_NNP 2005_CD Country_NN share_NN capital_NN held_VBD Principal_NN activity_NN UK_NNP 1_CD AstraZeneca_NNP UK_NNP Limited_NNP England_NNP 100_CD Research_NNP and_CC development_NN ,_, manufacturing_NN ,_, marketing_NN AstraZeneca_NNP Insurance_NNP Company_NNP Limited_NNP England_NNP 100_CD Insurance_NNP and_CC reinsurance_NN underwriting_NN AstraZeneca_NNP Treasury_NNP Limited_NNP England_NNP 100_CD Treasury_NNP Continental_NNP Europe_NNP NV_NNP AstraZeneca_NNP SA_NNP Belgium_NNP 100_CD Manufacturing_NNP ,_, marketing_NN AstraZeneca_NNP Dunkerque_NNP Production_NNP SCS_NNP France_NNP 100_CD Manufacturing_NNP AstraZeneca_NNP SAS_NNP France_NNP 100_CD Research_NNP ,_, manufacturing_NN ,_, marketing_NN AstraZeneca_NNP GmbH_NNP Germany_NNP 100_CD Development_NNP ,_, manufacturing_NN ,_, marketing_NN AstraZeneca_NNP Holding_NNP GmbH_NNP Germany_NNP 100_CD Manufacturing_NNP ,_, marketing_NN AstraZeneca_NNP SpA_NNP Italy_NNP 100_CD Manufacturing_NNP ,_, marketing_NN AstraZeneca_NNP Farmaceutica_NNP Spain_NNP SA_NNP Spain_NNP 100_CD Manufacturing_NNP ,_, marketing_NN AstraZeneca_NNP AB_NNP Sweden_NNP 100_CD Research_NNP and_CC development_NN ,_, manufacturing_NN ,_, marketing_NN AstraZeneca_NNP BV_NNP The_NNP Netherlands_NNP 100_CD Marketing_NNP The_DT Americas_NNP AstraZeneca_NNP Canada_NNP Inc._NNP ._.
Canada_NNP 100_CD Research_NNP ,_, manufacturing_NN ,_, marketing_NN IPR_NNP Pharmaceuticals_NNP Inc._NNP ._.
Puerto_NNP Rico_NNP 100_CD Development_NNP ,_, manufacturing_NN ,_, marketing_NN AstraZeneca_NNP LP_NNP US_NNP 99_CD Research_NNP and_CC development_NN ,_, manufacturing_NN ,_, marketing_NN AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP US_NNP 100_CD Research_NNP and_CC development_NN ,_, manufacturing_NN ,_, marketing_NN Zeneca_NNP Holdings_NNP Inc._NNP ._.
US_NNP 100_CD Manufacturing_NNP ,_, marketing_NN Asia_NNP ,_, Africa_NNP &_CC Australasia_NNP AstraZeneca_NNP Pty_NNP Limited_NNP Australia_NNP 100_CD Development_NNP ,_, manufacturing_NN ,_, marketing_NN AstraZeneca_NNP KK_NNP Japan_NNP 80_CD Manufacturing_NNP ,_, marketing_NN 1_CD Shares_NNP held_VBD directly_RB The_DT companies_NNS and_CC other_JJ entities_NNS listed_VBN above_RB are_VBP those_DT whose_WP$ results_NNS or_CC financial_JJ position_NN principally_RB affected_VBD the_DT figures_NNS shown_VBN in_IN the_DT Group_NNP Financial_NNP Statements_NNP ._.
A_DT full_JJ list_NN of_IN subsidiaries_NNS ,_, joint_JJ ventures_NNS and_CC associates_NNS will_MD be_VB annexed_VBN to_TO the_DT Companys_NNPS next_JJ annual_JJ return_NN filed_VBN with_IN the_DT Registrar_NNP of_IN Companies_NNS ._.
The_DT country_NN of_IN registration_NN or_CC incorporation_NN is_VBZ stated_VBN alongside_IN each_DT company_NN ._.
The_DT accounting_NN year_NN ends_NNS of_IN subsidiaries_NNS and_CC associates_NNS are_VBP 31_CD December_NNP ,_, except_IN for_IN Aptium_NNP Oncology_NNP ,_, Inc._NNP which_WDT ,_, owing_VBG to_TO local_JJ conditions_NNS and_CC to_TO avoid_VB undue_JJ delay_NN in_IN the_DT preparation_NN of_IN the_DT Financial_NNP Statements_NNP ,_, is_VBZ 30_CD November_NNP ._.
AstraZeneca_NNP operates_VBZ through_IN 236_CD subsidiaries_NNS worldwide_JJ ._.
The_DT Group_NNP Financial_NNP Statements_NNP consolidate_VB the_DT Financial_NNP Statements_NNP of_IN AstraZeneca_NNP PLC_NNP and_CC its_PRP$ subsidiaries_NNS at_IN 31_CD December_NNP 2005_CD ._.
Products_NNPS are_VBP manufactured_VBN in_IN 19_CD countries_NNS worldwide_JJ and_CC are_VBP sold_VBN in_IN over_IN 100_CD countries_NNS ._.
